Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Riedell

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Expert Opinion on Drug Safety|May 14, 2014
A drug safety evaluation of rituximab and risk of hepatitis BPeter Riedell, Kenneth R Carson
The Neurologist|March 2, 2018
Diagnostic Evaluation in Primary CNS LymphomaRimas V Lukas, Peter Riedell, Peleg M Horowitz, et al.
American Journal of Hematology|July 1, 2016
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapyDaphne Y Xiao, Suhong Luo, Katiuscia O'Brian, et al.
Haematologica|December 16, 2021
Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulatorsKevin S Tanager, Jovian Yu, Brian C-H Chiu, et al.
British Journal of Haematology|July 22, 2014
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisoneArun Ganti, Weijian Liu, Suhong Luo, et al.
Leukemia & Lymphoma|June 19, 2015
Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapyKatiuscia O'Brian, Suhong Luo, Arun Ganti, et al.
Journal of the National Cancer Institute|July 7, 2016
Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States VeteransDaphne Y Xiao, Suhong Luo, Katiuscia O'Brian, et al.
Cold Spring Harbor Molecular Case Studies|May 6, 2016
A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemiaCharles Lu, Peter Riedell, Christopher A Miller, et al.
Bone Marrow Transplantation|January 30, 2020
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survivalShawn Kothari, Andrew S Artz, Sang Mee Lee, et al.
Journal of Geriatric Oncology|January 24, 2015
Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphomaKenneth R Carson, Peter Riedell, Ryan Lynch, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Safety|May 14, 2014
A drug safety evaluation of rituximab and risk of hepatitis BPeter Riedell, Kenneth R Carson
The Neurologist|March 2, 2018
Diagnostic Evaluation in Primary CNS LymphomaRimas V Lukas, Peter Riedell, Peleg M Horowitz, et al.
American Journal of Hematology|July 1, 2016
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapyDaphne Y Xiao, Suhong Luo, Katiuscia O'Brian, et al.
Haematologica|December 16, 2021
Loss of 5-hydroxymethylcytosine expression is near-universal in B-cell lymphomas with variable mutations in epigenetic regulatorsKevin S Tanager, Jovian Yu, Brian C-H Chiu, et al.
British Journal of Haematology|July 22, 2014
Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisoneArun Ganti, Weijian Liu, Suhong Luo, et al.
Leukemia & Lymphoma|June 19, 2015
Short- and Long-term weight changes among United States veterans with diffuse large B-cell lymphoma treated with CHOP chemotherapyKatiuscia O'Brian, Suhong Luo, Arun Ganti, et al.
Journal of the National Cancer Institute|July 7, 2016
Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States VeteransDaphne Y Xiao, Suhong Luo, Katiuscia O'Brian, et al.
Cold Spring Harbor Molecular Case Studies|May 6, 2016
A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemiaCharles Lu, Peter Riedell, Christopher A Miller, et al.
Bone Marrow Transplantation|January 30, 2020
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survivalShawn Kothari, Andrew S Artz, Sang Mee Lee, et al.
Journal of Geriatric Oncology|January 24, 2015
Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphomaKenneth R Carson, Peter Riedell, Ryan Lynch, et al.
Pageof 2